Judith Raimbourg

机构：Institut de Cancérologie de l'Ouest · ORCID：0000-0003-2950-490X

发表论文 190 篇 · 总被引 2770 次 · h-index 20

代表论文

• Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer (2026 · Journal for ImmunoTherapy of Cancer · 被引 2)
• Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer (2026 · Clinical Cancer Research · 被引 1)
• Parkinsonism as a Potential Neurologic Immune-Mediated Adverse Event of Immune Checkpoint Inhibitors (2026 · Neurology Neuroimmunology & Neuroinflammation)
• Supplementary Figure S2 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer (2026)
• Supplementary Figure S5 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer (2026)
• Supplementary Figure S1 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer (2026)